Analytical Data
-
Gene name
Deoxyhypusine synthase/DHS
- Application
-
Alternative Names
MIG13; DHS; DS; Migration-Inducing Gene 13
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P49366
-
Expression Region
Met1~Asp369
-
Molecular Weight
45kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Deoxyhypusine synthase (DHS) is an essential enzyme that catalyzes the first step in the hypusine biosynthesis pathway, specifically the conversion of the translation factor eIF5A's lysine residue to deoxyhypusine. This post-translational modification is crucial for eIF5A's role in protein synthesis and cellular proliferation. Recent research has highlighted DHS as a potential target for cancer therapy, as its activity is often upregulated in various malignancies, contributing to uncontrolled cell growth. The recombinant production of DHS allows for in-depth structural and functional studies, aiding in the understanding of its enzymatic mechanism and its regulatory processes. Investigating the properties of DHS in a recombinant form not only facilitates the exploration of its interactions with substrates and inhibitors but also supports the development of potent pharmacological agents aimed at modulating its activity. By elucidating the role of DHS in cellular physiology and its implications in disease contexts, researchers aim to harness this knowledge for therapeutic advances, particularly in cancer treatments, where selective inhibition of DHS could potentially lead to diminished tumor growth and improved patient outcomes. The ongoing studies on recombinant DHS underscore its significance in both basic research and drug development, making it a pivotal focus within the fields of biochemistry, molecular biology, and medical science.
